{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053878","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2026-08-06T12:02:17+00:00","discovered_at":"2026-08-06T12:05:14.508599+00:00","generated_at":"2026-08-06T12:05:45.862517+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Prime Medicine Q2 net loss $42.1M; IND/CTA clearances for PM577a, arbitration win for PM647","bullets":["Net loss of $42.1M for Q2 2026 vs $52.6M in Q2 2025; R&D expenses $33.4M.","Cash, equivalents, investments, restricted cash $108.8M as of June 30, 2026; runway into 2027.","FDA cleared IND for PM577a in Wilson disease; Medsafe cleared CTA in New Zealand; global Phase 1/2 study startup underway.","Arbitration with Beam Therapeutics resolved favorably; PM647 rights secured; IND/CTA submission expected Q3 2026.","FDA granted RMAT designation to PM359 for CGD; BLA submission planned for 1H 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053878","json":"https://secwatch.observer/filing/0001628280-26-053878.json","markdown":"https://secwatch.observer/filing/0001628280-26-053878.md","text":"https://secwatch.observer/filing/0001628280-26-053878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026053878/0001628280-26-053878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026053878/prme-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:05:45.862517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}